Merck KGaA
Develops and supplies life science research products, pharmaceuticals for oncology and rare diseases, and advanced materials for semiconductor manufacturing.
As of Jul 17, 2026
Executive summary
Merck KGaA is a diversified healthcare company traded on XETRA, with operations spanning pharmaceuticals, life sciences, and performance materials. The stock shows a neutral technical bias, though it has gained 25.7% over the past year and trades at a market capitalisation of €60.0 billion. At €136.30, it declined 1.2% today.
Price history
As of Jul 17, 2026
Performance
-1.20%
-2.43%
+2.44%
+18.28%
+13.40%
+25.71%
As of Jul 17, 2026
Technical indicators
- 44.9
- -1.28Bearish
- 50: 133.89 · 200: 119.96Bullish
- €131.40 / €148.65
Technical Bias
Merck KGaA is trading at €136.30 with a mixed technical picture: the 50-day moving average sits above the 200-day (bullish structure), but the MACD histogram is negative (bearish momentum), whilst RSI at 44.9 sits neutral. This derived technical read suggests equilibrium between upside and downside pressure, with support at €131.40 and resistance at €148.65.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 17, 2026
Fundamentals
- €60.0B
- 23.66
- €5.83
- 12.08%
- -2.8%
- €2.35B
- 0.83
- €98.72 – €148.65
- 1.57%
- Apr 27, 2026
- Aug 6, 2026 (19 days)
As of Jul 17, 2026
Upcoming catalysts
- Earnings report
As of Jul 17, 2026
Latest news
As of Jul 17, 2026
Short-term outlook
Merck KGaA shares have edged up 2.4% over the past month, but the near-term picture is mixed: MACD points to bearish momentum while RSI sits neutral at 44.9, even as the stock holds above both its 50-day and 200-day averages. Over the coming weeks, watch how price behaves around support at €131.40 and resistance at €148.65, with no earnings catalyst due until August 2026.
Medium-term outlook
Merck KGaA's revenue slipped 2.8% year-on-year, though the business still holds a respectable 12.1% profit margin and pays a 1.6% dividend yield. At a P/E of 23.66, the market isn't pricing in much growth right now, and with the technical picture reading neutral, there's no clear directional lean to point to over the coming quarters.
Key risks
- Revenue declined 2.8% year on year, which points to some near-term top-line pressure despite healthy profit margins.
- The stock trades at a current price of €136.30, still some way below its 52-week high of €148.65, showing the shares have room to move in either direction.
- Pipeline progress, such as the breakthrough therapy designation for Enpatoran, carries the usual regulatory and clinical uncertainty until further development milestones are confirmed.
- As a diversified healthcare and life sciences business, Merck KGaA remains exposed to competitive dynamics in areas like cell isolation and lab testing services, where new market entrants and facility investments from peers can shift industry positioning.
About Merck KGaA
Merck KGaA is a German healthcare company operating in the specialty and generic drug manufacturing space. Listed on the XETRA exchange under the ticker MRK, the company holds a market capitalisation of €60.0 billion, placing it among the larger names in Europe's pharmaceutical sector. Its scale reflects a broad footprint across drug development and manufacturing, serving markets that depend on both branded and generic treatments.
The company's key figures give a snapshot of how the market currently values it. A price-to-earnings ratio of 23.66 shows what investors are paying relative to Merck KGaA's earnings, while a dividend yield of +1.6% reflects the portion of returns paid out to shareholders. Together, these figures offer a starting point for understanding how the stock is priced and how it rewards investors, within the broader context of the healthcare sector.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.